Literature DB >> 16818180

Detection of circulating tumor cells in patients with renal cell carcinoma by reverse transcriptase polymerase chain reaction for G250/MNCA-9: results of a prospective trial.

Carsten-Henning Ohlmann1, Enver Ozgür, Andres Jan Schrader, Lutz Konrad, Rainer Hofmann, Udo Engelmann, Axel Heidenreich.   

Abstract

OBJECTIVES: Radical nephrectomy displays the standard procedure for patients with localized renal cell carcinoma. The transperitoneal approach is often favored compared to the retroperitoneal approach because of the early ligation of the renal vessels, thereby tumor cell shedding by manipulation of the tumor is thought to be avoided. The aim of our study was to investigate the influence of the surgical technique on intraoperative tumor cell shedding. Furthermore, we evaluated the clinical course of the patients being operated on with either method in terms of complications, postoperative recovery, and hospital stay.
METHODS: A total of 55 consecutive patients with renal tumors suspicious for malignancies were evaluated for this study. Peripheral blood samples were obtained from 44 patients at admission, intraoperatively (before and after kidney removal), and before discharge. Ribonucleic acid was extracted, converted to complementary deoxyribonucleic acid, and reverse transcriptase polymerase chain reaction (RT-PCR) with primers specific for G250/MNCA-9 was performed. Data regarding the clinical course of the patients were analyzed retrospectively by reviewing patient files.
RESULTS: The clinical course for patients undergoing retroperitoneal nephrectomy was statistically different compared to the transperitoneal approach group regarding operating time and duration of drains, favoring the retroperitoneal approach group. Evaluation of MNCA-9 RT-PCR revealed no difference according to operative technique, tumor-nodes-metastasis, or clinical tumor stage. Despite this result, we found positive RT-PCR signals for MNCA-9 in patients with transitional cell cancer of the renal pelvis and benign renal lesions.
CONCLUSIONS: There is no clinical relevant difference between the transperitoneal and retroperitoneal approaches for radical nephrectomy. Furthermore, the retroperitoneal approach does not bear the risk of intraoperative tumor cell shedding by the handling of the tumor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818180     DOI: 10.1016/j.urolonc.2005.10.004

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  5 in total

Review 1.  [Operative treatment of renal cell carcinoma].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

2.  Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma.

Authors:  Martina Takacova; Maria Bartosova; Lucia Skvarkova; Miriam Zatovicova; Ivana Vidlickova; Lucia Csaderova; Monika Barathova; Jan Breza; Peter Bujdak; Jaromir Pastorek; Jan Breza; Silvia Pastorekova
Journal:  Oncol Lett       Date:  2012-10-26       Impact factor: 2.967

3.  Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma.

Authors:  Jinbo Song; Zhe Yu; Bingqi Dong; Mingkai Zhu; Xiaofeng Guo; Yongkang Ma; Shiming Zhao; Tiejun Yang
Journal:  World J Surg Oncol       Date:  2021-05-25       Impact factor: 2.754

4.  Microarray-based identification and RT-PCR test screening for epithelial-specific mRNAs in peripheral blood of patients with colon cancer.

Authors:  Rossella Solmi; Giampaolo Ugolini; Giancarlo Rosati; Simone Zanotti; Mattia Lauriola; Isacco Montroni; Marco del Governatore; Antonello Caira; Mario Taffurelli; Donatella Santini; Domenico Coppola; Lia Guidotti; Paolo Carinci; Pierluigi Strippoli
Journal:  BMC Cancer       Date:  2006-10-20       Impact factor: 4.430

5.  Single-cell genetic analysis validates cytopathological identification of circulating cancer cells in patients with clear cell renal cell carcinoma.

Authors:  Lucile Broncy; Basma Ben Njima; Arnaud Méjean; Christophe Béroud; Khaled Ben Romdhane; Marius Ilie; Veronique Hofman; Jane Muret; Paul Hofman; Habiba Chaabouni Bouhamed; And Patrizia Paterlini-Bréchot
Journal:  Oncotarget       Date:  2018-04-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.